Skip to main content
HCA
NYSE Industrial Applications And Services

HCA Previews Q2 Revenue of $20.23B, Cuts Full-Year EPS Guidance on Payer Mix Headwinds

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$368
Mkt Cap
$86.682B
52W Low
$330
52W High
$556.52
52W Position info
12% above low
Off High info
34% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

HCA is trading near its 52-week low of $330 (12% above the low).

Summary

HCA Healthcare reported preliminary Q2 revenue of $20.23B and EPS of $7.62, but cut full-year 2026 EPS guidance to $28.70-$30.50 due to a $400M hit from uninsured patients, partially offset by a $400M Medicaid benefit.


Key Events · Earnings and Guidance · HCA

  • Q2 Revenue Tops $20B

    Preliminary Q2 2026 revenue of ~$20.23B, up 8.7% YoY, with net income of $1.699B ($7.62 per diluted share) and Adjusted EBITDA of $4.027B.

  • Full-Year EPS Guidance Cut

    2026 diluted EPS guidance lowered to $28.70-$30.50 from $29.10-$31.50, with net income now seen at $6.3B-$6.7B vs. prior $6.495B-$7.035B.

  • $400M Payer Mix Headwind

    Unfavorable shift toward uninsured patients, primarily from health insurance exchange losses, reduced pre-tax income by ~$400M in Q2; full-year exchange impact now estimated at ($1.0B)-($1.2B).

  • $400M Medicaid Offset

    Recognized ~$400M incremental net benefit from Medicaid Supplemental Payment Programs, mainly Florida, covering Oct 2024–Jun 2026; full-year benefit now seen at $300M-$500M.


Analysis · HCA · Industrial Applications And Services

HCA Healthcare pre-announced second-quarter revenue of approximately $20.23 billion, beating consensus, but lowered its full-year 2026 earnings guidance. The company now expects diluted EPS of $28.70 to $30.50, down from $29.10 to $31.50, driven by a $400 million unfavorable payer mix shift from uninsured patients and partially offset by a $400 million benefit from Medicaid supplemental payments. The guidance cut reflects a material deterioration in the payer environment that outweighs the one-time Medicaid boost, signaling ongoing pressure on profitability.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HCA was trading at $368.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $86.7B. The 52-week trading range was $330.00 to $556.52. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HCA - Latest Insights

HCA
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $499.00
Real-time Price: $476.00 info
Change: -$23.00 (-5%) info
Market Cap: $99.343B info
HCA
Oct 29, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $478.08
Real-time Price: $476.00 info
Change: -$2.08 (-0.44%) info
Market Cap: $99.343B info
HCA
Oct 27, 2026, 1:11 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $443.28
Real-time Price: $476.00 info
Change: +$32.72 (+7%) info
Market Cap: $99.343B info
HCA
Oct 27, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $485.00
Real-time Price: $476.00 info
Change: -$9.00 (-2%) info
Market Cap: $99.343B info
HCA
Oct 27, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.95
Real-time Price: $476.00 info
Change: +$15.05 (+3%) info
Market Cap: $99.343B info